Cargando…

The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies

Cancer associated thrombosis (CAT) is associated with significant morbidity and mortality, highlighting an unmet clinical need to improve understanding of the pathophysiology of CAT. Multiple myeloma (MM) is associated with one of the highest rates of thrombosis despite widespread use of thromboprop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Comerford, Claire, Glavey, Siobhan, Quinn, John, O’Sullivan, Jamie M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546473/ https://www.ncbi.nlm.nih.gov/pubmed/35644028 http://dx.doi.org/10.1111/jth.15773

Ejemplares similares

Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma
por: Comerford, Claire, et al.
Publicado: (2022)

Utility of a high VWF:FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice
por: Raquet, Elmar, et al.
Publicado: (2015)

Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors
por: Bravo, M I, et al.
Publicado: (2014)

Induction Treatment in Transplant-eligible Multiple Myeloma
por: Quinn, J., et al.
Publicado: (2021)

Common VWF sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD
por: Flood, Veronica H., et al.
Publicado: (2018)

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
por: Ay, Cihan, et al.
Publicado: (2022)

Genetic Abnormalities in Extramedullary Multiple Myeloma
por: McAvera, Roisin, et al.
Publicado: (2023)

Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels
por: Antoni, Guillemette, et al.
Publicado: (2011)

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2019)

Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance
por: Doherty, Dearbhla, et al.
Publicado: (2022)

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
por: Swan, Dawn, et al.
Publicado: (2023)

Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study
por: Bravo, Maria Isabel, et al.
Publicado: (2022)

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A
por: Trevisan, Brady, et al.
Publicado: (2021)

Effectiveness of long‐term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease
por: Rugeri, Lucia, et al.
Publicado: (2022)

PB1996: TREATMENT PATHWAYS AT FIRST RELAPSE POST-ASCT IN MULTIPLE MYELOMA: IMPACT OF MAINTENANCE THERAPY ON TREATMENT OPTIONS
por: Duane, C., et al.
Publicado: (2022)

Gene expression profiling as a prognostic tool in multiple myeloma
por: Black, Harmony, et al.
Publicado: (2021)

ADAMTS13 regulation of VWF multimer distribution in severe COVID‐19
por: Ward, Soracha E., et al.
Publicado: (2021)

Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
por: Shackleton, Louisa, et al.
Publicado: (2020)

Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients
por: Barrett, Aisling, et al.
Publicado: (2021)

Emergence of chronic myeloid leukemia following autologous stem cell transplantation in a young woman with multiple myeloma
por: Barrett, Aisling, et al.
Publicado: (2018)

Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2022)

Adoptive Immunotherapy and High-Risk Myeloma
por: Duane, Catherine, et al.
Publicado: (2023)

FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes
por: van der Flier, Arjan, et al.
Publicado: (2015)

Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders
por: Windyga, Jerzy, et al.
Publicado: (2022)

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)
por: Auerswald, Guenter, et al.
Publicado: (2020)

Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
por: De Padua, Valeria, et al.
Publicado: (2020)

Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)
por: Lissitchkov, Toshko J., et al.
Publicado: (2017)

Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis
por: Pagliari, Maria Teresa, et al.
Publicado: (2021)

New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF
por: Liu, Zhi-Yan, et al.
Publicado: (2023)

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
por: Lalezari, S, et al.
Publicado: (2014)

VWF springs into action
por: Wells, William A.
Publicado: (2006)

Comprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma
por: Weng, Jiren, et al.
Publicado: (2023)

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
por: Schriewer, Levin, et al.
Publicado: (2020)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

VWF, Platelets and the Antiphospholipid Syndrome
por: Huang, Shengshi, et al.
Publicado: (2021)

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence
por: Leksa, Nina C., et al.
Publicado: (2019)

Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies
por: Mahimainathan, Lenin, et al.
Publicado: (2020)

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia
por: Allegra, Alessandro, et al.
Publicado: (2021)

Macrophage Galactose Lectin Contributes to the Regulation of FVIII (Factor VIII) Clearance in Mice—Brief Report
por: Ward, Soracha E., et al.
Publicado: (2023)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q786f6ke4k014j7sv7075sm0ms